Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study [0.03%]
基于Ki67状态的用于II-III期乳腺癌的新辅助内分泌治疗联合序贯使用帕博西尼和化疗：一项开放性II期研究
Christina Engebrethsen,Synnøve Yndestad,Mari E Rasmussen et al.
Christina Engebrethsen et al.
Background: While neoadjuvant endocrine therapy (NET), with or without a CDK4/6 inhibitor, is an established treatment option for estrogen receptor-positive breast cancers, optimal patient selection and second-line treatm...
Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer [0.03%]
奥拉帕利联合帕博西尼-氟维司群与帕博西尼联合氟维司群一线治疗HR+/HER2-晚期乳腺癌的 cost-effectiveness 分析
Jiaming Zhu,Ye Ding,Zhengxiong Li et al.
Jiaming Zhu et al.
Purpose: This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR+/HER2-breast cancer patients with PIK3CA mutations from both U...
Beyond survival: Confronting the unmet needs in oncofertility care for young women with breast cancer [0.03%]
超越生存：年轻乳腺癌女性生育力保存未满足需求的挑战与应对
Sophie Richard,Megan Tesch,Nathalie LeVasseur
Sophie Richard
Comparative validation of PREDICT versions 3.1 and 2.2 for overall survival in the Dutch breast cancer population [0.03%]
PREDICT 3.1和2.2版本在荷兰乳腺癌人群中的总生存比较验证研究
Lara W A Vreven,Elfi M Verheul,Marissa C van Maaren et al.
Lara W A Vreven et al.
Background: PREDICT Breast is a clinical decision-support tool estimating prognosis and the absolute benefit of adjuvant systemic therapies in early breast cancer. PREDICT v2.2 is recommended in Dutch guidelines. Both v2....
Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patients [0.03%]
荷兰五 character Breast Cancer患者诊断后五年内局部、区域和对侧乳房肿瘤复发的流行趋势：一项包括121347例患者的基于人群的研究
J Meijer,H J G D van den Bongard,L B Koppert et al.
J Meijer et al.
Background: The objective was to provide an overview of trends in five-year local recurrence (LR), regional recurrence (RR) and contralateral breast cancer (CBC) rates in the Netherlands from 2003 to 2008 and 2012-2016. ...
Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes [0.03%]
早期 Luminal 期乳腺癌省略哨兵淋巴结活检对手术后的治疗决策和预后的影响
Martin Heidinger,Tibor A Zwimpfer,Florian S Halbeisen et al.
Martin Heidinger et al.
Background: Sentinel lymph node biopsy (SLNB) omission is safe in many patients with small, clinically and imaging node-negative (cN0/iN0), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-n...
Antonella Grasso,Andrea Salerno,Alessandra Micera et al.
Antonella Grasso et al.
Purpose: To investigate ocular surface alterations associated with oncological therapy in patients with hormone receptor-positive (HR+) breast cancer. Met...
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy [0.03%]
化疗和曲妥珠单抗的时机及新辅助治疗的疗效与辅助性卵巢功能抑制和他莫昔芬在激素受体和HER2阳性乳腺癌前期患者中的应用关系研究
Ayelet Shai,Hans Wildiers,Claudio Venieri et al.
Ayelet Shai et al.
Background: The benefit of adjuvant ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients with hormone receptor positive, HER2 positive (HR+/HER2+) breast cancer (BC) is unclear. We ai...
Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients [0.03%]
绝经后ER+/HER2-乳腺癌患者基于深度学习的AI模型乳腺癌风险分层验证研究
Sandra Sinius Pouplier,Abhinav Sharma,Pekka Ruusuvuori et al.
Sandra Sinius Pouplier et al.
Background: Breast cancer prognostication is crucial for treatment decisions, and the Nottingham Histologic Grade (NHG) system is widely used. However, NHG suffers from interobserver variability, and its division into thr...
Nodal response to neoadjuvant therapy predicts prognosis of breast cancer patients with clinically positive internal mammary nodes [0.03%]
新辅助治疗的淋巴结反应可预测内乳淋巴结阳性乳腺癌患者的预后
Zhe Xu,Lu Cao,Wei-Xiang Qi et al.
Zhe Xu et al.
Purpose: To evaluate survival outcomes and prognostic factors in breast cancer patients with clinically positive internal mammary lymph nodes (cIMN+) after combined-modality therapy, and to identify indicators for interna...